Phibro Animal Health (PAHC) Bank of America Global Healthcare Conference 2026 summary

Financial performance and portfolio growth

• Achieved 10% overall revenue growth in the quarter, with the MFA segment up 25% and legacy portfolio up 5%.

• Vaccine portfolio grew 16% and Nutritional Specialties increased 8%.

• EBITDA growth was 11%, with broad-based strength across geographies and species.

• North America performed particularly well, and the business is now more balanced by species and region after recent acquisitions.

• Guidance was reiterated and the lower end was raised.

Regulatory and operational updates

• Brazil’s regulator removed growth promotion claims for certain antibiotics, impacting two products, mainly virginiamycin.

• A 180-day transition period allows continued sales while awaiting new therapeutic claims.

• Short-term revenue impact expected in Brazil, with recovery anticipated over several years.

• Previous transitions in other countries provide operational experience for managing this change.

Sustainability initiatives and new product launch

• Launched a sustainability platform and introduced Verratain, a carbon-negative feed additive developed with VAXA Technologies.

• Product targets Scope 3 emissions reductions for ag supply chains, addressing a $100–$200 billion market opportunity.

• Initial trials will be in Europe, with U.S. as a future focus; product does not alter animal physiology.

• Pricing expected to align with $40–$100 per ton of carbon removed, adding $0.10–$0.20 per cheeseburger.

• Platform expected to expand with additional sustainability products in the future.